Arthur Becker has played a top role in a number of industries. He has been in the technology industry, both as the Chief Executive Officer and Chairman of Zinio as well as the CEO of Navisite. He has also been a highly successful stock market trader on Wall Street. For several years he was a senior advisor to the Vera Wang Fashion Company. He was married to Vera Wang for 23 years prior to the couple splitting in 2012.
Today, Arthur Becker is the Managing Member of Madison Partners, LLC. At this firm, he invests in luxury real estate projects in both New York City and Miami, Florida. He also invests in startup biotechnology companies. He established Madison Partners in 2011 and now has over $500 million invested in real estate in just New York City. He credits some of his success to his time at the Vera Wang Fashion Company where he says he learned about fashion as well as design.
The way he makes money in the real estate industry is by buying high-end properties that he then renovates. After the renovation is completed he either leases the property out to others or sells it for a profit. He uses his extensive experience in business in order to identify good opportunities to make money in the real estate industry.
Among his latest projects is a luxury townhouse real estate project he is developing in New York City’s Tribeca district. Once completed the project will feature 8 high-end residential units, one of which is going to be a duplex. Once the building is completed he estimates the value of the property will be around $52.5 million.
Arthur Becker has said that, although he doesn’t possess any medical training, he has gathered enough knowledge about the biotechnology industry that he feels comfortable investing in it. The biotechnology industry has been rapidly changing over the last several years, especially with new drugs that target diseased cells rather than conventional drugs which can’t differentiate between diseased cells and healthy ones. Becker has successfully invested in a number of companies that are creating these next-generation cures. More details can be found on Bloomberg.